Human IgG1 antibodies suppress angiogenesis in a target-independent manner

Aberrant angiogenesis is implicated in diseases affecting nearly 10% of the world’s population. The most widely used anti-angiogenic drug is bevacizumab, a humanized IgG1 monoclonal antibody that targets human VEGFA. Although bevacizumab does not recognize mouse Vegfa, it inhibits angiogenesis in mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogdanovich, Sasha, Kim, Younghee, Mizutani, Takeshi, Yasuma, Reo, Tudisco, Laura, Cicatiello, Valeria, Bastos-Carvalho, Ana, Kerur, Nagaraj, Hirano, Yoshio, Baffi, Judit Z, Tarallo, Valeria, Li, Shengjian, Yasuma, Tetsuhiro, Arpitha, Parthasarathy, Fowler, Benjamin J, Wright, Charles B, Apicella, Ivana, Greco, Adelaide, Brunetti, Arturo, Ruvo, Menotti, Sandomenico, Annamaria, Nozaki, Miho, Ijima, Ryo, Kaneko, Hiroki, Ogura, Yuichiro, Terasaki, Hiroko, Ambati, Balamurali K, Leusen, Jeanette HW, Langdon, Wallace Y, Clark, Michael R, Armour, Kathryn L, Bruhns, Pierre, Verbeek, J Sjef, Gelfand, Bradley D, De Falco, Sandro, Ambati, Jayakrishna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763941/
https://www.ncbi.nlm.nih.gov/pubmed/26918197
http://dx.doi.org/10.1038/sigtrans.2015.1

Ejemplares similares

Ejemplares similares